Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunostaining and Ciliary Movement Analysis in Primary Ciliary Dyskinesia With a Homozygous Deletion Involving Exons 1-4 of <i>DRC1</i>: A Case Report.

Respirology case reports·2026
Same author

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in Japan.

International journal of clinical oncology·2025
Same author

Case report: Severe arrhythmogenic cardiomyopathy in a young girl with compound heterozygous <i>DSG2</i> and <i>MYBPC3</i> variants with a 6-year follow-up.

Frontiers in genetics·2025
Same author

Analysis of endometrial liquid‑based cytology samples to detect somatic mutations and classify ovarian cancer.

Oncology letters·2025
Same author

Two Pediatric Cases of Primary Ciliary Dyskinesia Caused by Loss-of-Function Variants in Oral-Facial-Digital Syndrome Gene, <i>OFD1</i>.

Case reports in genetics·2024
Same author

Practical guide for the diagnosis and management of primary ciliary dyskinesia.

Auris, nasus, larynx·2024

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

[Pharmacogenomics].

Kaname Nakatani1, Tsutomu Nobori2

  • 1Division of Clinical Laboratory, Mie University Hospital, Tsu 514-8507, Japan. nakatani@clin.medic.mie-u.ac.jp

Rinsho Byori. the Japanese Journal of Clinical Pathology
|January 24, 2014
PubMed
Summary

Pharmacogenomics advances personalized medicine by linking genetic variation to drug response. Companion diagnostics, crucial for targeted therapies, are needed for common diseases, requiring multiplex testing for broader application.

Area of Science:

  • Genomics and Precision Medicine
  • Pharmacology and Therapeutics

Context:

  • Pharmacogenomics is advancing personalized medicine, linking genetic variations to individual drug responses.
  • Innovations in genetic analysis support the clinical development of pharmacogenomics.
  • Molecular target drugs are standard in cancer therapy, with efficacy predicted by companion diagnostics.

Purpose:

  • To highlight the role of pharmacogenomics and companion diagnostics in personalized medicine.
  • To discuss the current limitations of companion diagnostics, particularly for common diseases.
  • To emphasize the need for multiplex companion diagnostics for future personalized medicine expansion.

Summary:

  • Pharmacogenomics studies how genetic variations affect drug responses, ranging from adverse reactions to lack of efficacy.

More Related Videos

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

41.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

41.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K
  • Companion diagnostics identify molecular targets to guide treatment decisions, improving drug efficacy and safety.
  • While prevalent in cancer, companion diagnostics are lacking for multifactorial common diseases, necessitating multiplex testing.

    • Impact:

    • Companion diagnostic co-development accelerates drug development, yielding safer, more effective treatments cost-effectively.
    • The expansion of personalized medicine relies on developing companion diagnostics for common, multifactorial diseases.
    • Multiplex companion diagnostics are anticipated to enable broader personalized medicine applications beyond targeted cancer therapies.